Compositions and soft tissue replacement methods

1. A composition comprising:

a) adipose tissue; and

b) a therapeutically effective amount of a compound of the structure of formula I

wherein each dashed line represents the presence or absence of a bond;

R 1 , R 2 and R 3 are each independently selected from H or C 1 -C 6 alkyl;

R 6 is CO 2 H, CO 2 R 7 , CON(R 7 ) 2 , CONHCH 2 CH 2 OH, CON(CH 2 CH 2 OH) 2 , CH 2 OR 7 , P(O)(OR 7 ) 2 ,

R 7 is independently H, C 1 -C 6 alkyl or C 2 -C 6 alkenyl;

X and Y are each independently selected from H, OH, ═O, Cl, Br, I, or CF 3 ;

Z 1 and Z 2 are each independently selected from CH or N;

W 1 and W 2 are each independently selected from CH, CH 2 , aryl or substituted aryl, heteroaryl, substituted heteroaryl;

m is 0, 1, 2, 3 or 4;

o is 0, 1, 2, 3, 4, 5 or 6;

p is 0 or 1; and

V is methyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

wherein, when V is methyl, Z 1 or Z 2 is N;

a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof.

2. The composition of claim 1 , wherein the compound has the structure of formula II

wherein each dashed line represents the presence or absence of a bond;

R 1 , R 2 and R 3 are each independently selected from H or C 1 -C 6 alkyl;

R 4 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl;

X and Y are each independently selected from H, OH, ═O, Cl, Br, I, or CF 3 ;

Z 1 and Z 2 are each independently selected from CH or N;

W 1 and W 2 are each independently selected from CH, CH 2 , aryl or substituted aryl, heteroaryl, substituted heteroaryl;

m is 0, 1, 2, 3 or 4;

o is 0, 1, 2, 3, 4, 5 or 6;

p is 0 or 1; and

V is methyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

wherein, when V is methyl, Z 1 or Z 2 is N;

a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof.

3. The composition of claim 1 , wherein V is

wherein U is C, N, O, or S; R 5 is halogen, C 1 -C 6 alkyl, or C 2 -C 6 alkenyl; and n is 0-7.

4. The composition of claim 3 , wherein U is S; R 5 is F, Cl, Br, or I; and n is 1, 2, or 3.

5. The composition of claim 1 , wherein W 2 is thiophene.

6. The composition of claim 1 , wherein the compound has the structure of formula III

wherein each dashed line represents the presence or absence of a bond;

R 1 , R 2 and R 3 are each independently selected from H or C 1 -C 6 alkyl;

R 4 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl;

W 1 and W 2 are each independently selected from CH, CH 2 , aryl or substituted aryl, heteroaryl, substituted heteroaryl;

m is 0, 1, 2, 3 or 4;

o is 0, 1, 2, 3 or 4;

p is 0 or 1; and

V is CH 3 , aryl, aryl or substituted aryl, heteroaryl, substituted heteroaryl;

a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable amine salt thereof.

7. The composition of claim 1 , wherein the compound has the structure of formula IV

wherein each dashed line represents the presence or absence of a bond;

R 1 , R 2 and R 3 are each independently selected from H or C 1 -C 6 linear alkyl;

R 4 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl;

m is 0, 1, 2, 3 or 4;

o is 0, 1, 2, 3 or 4;

p is 0 or 1; and

V is CH 3 , aryl, aryl or substituted aryl, heteroaryl, substituted heteroaryl;

a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof.

8. The composition of claim 1 , wherein the compound has the structure of formula V

wherein each dashed line represents the presence or absence of a bond;

R 4 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl;

o is 0, 1, 2, 3 or 4; and

V is CH 3 , aryl, aryl or substituted aryl, heteroaryl, substituted heteroaryl;

a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof.

9. The composition of claim 1 , wherein the compound is

a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof.

10. The composition of claim 1 , wherein the compound is incorporated into a drug delivery platform comprising a biodegradable polymer matrix.

11. The composition of claim 1 , wherein the biodegradable polymer matrix comprises a silk fibroin.

12. A method of treating a soft tissue condition of an individual, the method comprising the step of administering to a site of the soft tissue condition a composition comprising adipose tissue and a therapeutically effective amount of a compound of the structure of formula I

wherein each dashed line represents the presence or absence of a bond;

R 1 , R 2 and R 3 are each independently selected from H or C 1 -C 6 alkyl;

R 6 is CO 2 H, CO 2 R 7 , CON(R 7 ) 2 , CONHCH 2 CH 2 OH, CON(CH 2 CH 2 OH) 2 , CH 2 OR 7 , P(O)(OR 7 ) 2 ,

R 7 is independently H, C 1 -C 6 alkyl or C 2 -C 6 alkenyl;

X and Y are each independently selected from H, OH, ═O, Cl, Br, I, or CF 3 ;

Z 1 and Z 2 are each independently selected from CH or N;

W 1 and W 2 are each independently selected from CH, CH 2 , aryl or substituted aryl, heteroaryl, substituted heteroaryl;

m is 0, 1, 2, 3 or 4;

o is 0, 1, 2, 3, 4, 5 or 6;

p is 0 or 1; and

V is methyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

wherein when V is methyl, Z 1 or Z 2 is N;

a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof,

wherein administration of the composition promotes formation of a blood supply sufficient to support the transplanted tissue, thereby treating the soft tissue site.

13. The method of claim 12 , wherein the soft tissue condition is wherein the soft tissue condition is a breast tissue condition, a facial tissue condition, a neck condition, a skin condition, an upper arm condition, a lower arm condition, a hand condition, a shoulder condition, a back condition, a torso including abdominal condition, a buttock condition, an upper leg condition, a lower leg condition including calf condition, a foot condition including plantar fat pad condition, an eye condition, a genital condition, or a condition effecting another body part, region or area.

14. The method of claim 13 , wherein the breast tissue condition is a breast imperfection, a breast defect, a breast augmentation, or a breast reconstruction.

15. The method of claim 13 , wherein the facial tissue condition is a facial imperfection, a facial defect, a facial augmentation, or a facial reconstruction.

16. The method of claim 13 , wherein the facial soft tissue condition is a dermal divot, a sunken check, a thin lip, a nasal imperfection or defect, a retro-orbital imperfection or defect, a facial fold, a facial line, a facial wrinkle, or other size, shape or contour imperfection or defect of the face.

17. The method of claim 12 , wherein the soft tissue condition is urinary incontinence, fecal incontinence, or gastroesophageal reflux disease (GERD).

18. A method of treating a soft tissue condition of an individual, the method comprising the steps of

a) administering adipose tissue to a site of the soft tissue condition;

b) administering a therapeutically effective amount of a compound of the structure of formula I to the site of the soft tissue condition,

wherein each dashed line represents the presence or absence of a bond;

R 1 , R 2 and R 3 are each independently selected from H or C 1 -C 6 alkyl;

R 6 is CO 2 H, CO 2 R 7 , CON(R 7 ) 2 , CONHCH 2 CH 2 OH, CON(CH 2 CH 2 OH) 2 , CH 2 OR 7 , P(O)(OR 7 ) 2 ,

R 7 is independently H, C 1 -C 6 alkyl or C 2 -C 6 alkenyl;

X and Y are each independently selected from H, OH, ═O, Cl, Br, I, or CF 3 ;

Z 1 and Z 2 are each independently selected from CH or N;

W 1 and W 2 are each independently selected from CH, CH 2 , aryl or substituted aryl, heteroaryl, substituted heteroaryl;

m is 0, 1, 2, 3 or 4;

o is 0, 1, 2, 3, 4, 5 or 6;

p is 0 or 1; and

V is methyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

wherein when V is methyl, Z 1 or Z 2 is N;

a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable amine salt thereof,

wherein administration of the composition promotes formation of a blood supply sufficient to support the transplanted tissue, thereby treating the soft tissue site.

19. The method of claim 18 , wherein the soft tissue condition is wherein the soft tissue condition is a breast tissue condition, a facial tissue condition, a neck condition, a skin condition, an upper arm condition, a lower arm condition, a hand condition, a shoulder condition, a back condition, a torso including abdominal condition, a buttock condition, an upper leg condition, a lower leg condition including calf condition, a foot condition including plantar fat pad condition, an eye condition, a genital condition, or a condition effecting another body part, region or area.

20. The method of claim 19 , wherein the breast tissue condition is a breast imperfection, a breast defect, a breast augmentation, or a breast reconstruction.

21. The method of claim 19 , wherein the facial tissue condition is a facial imperfection, a facial defect, a facial augmentation, or a facial reconstruction.

22. The method of claim 19 , wherein the facial soft tissue condition is a dermal divot, a sunken check, a thin lip, a nasal imperfection or defect, a retro-orbital imperfection or defect, a facial fold, a facial line, a facial wrinkle, or other size, shape or contour imperfection or defect of the face.

23. The method of claim 18 , wherein the soft tissue condition is urinary incontinence, fecal incontinence, or gastroesophageal reflux disease (GERD).